Novel GLP-1 Peptide Analog APT3711

● APT3711 is a fully synthetic analog of GLP-1 (7-36) with unnatural amino acids incorporated to improve peptide stability and half-life.

● In rats, APT3711 demonstrated a half-life 62% and 45%longer compared to Semaglutide and Tirzepatide.

● In minipigs, APT3711 demonstrated a half-life 2.7 fold longer compared to Semaglutide .

● In DIO mouses, APT 3711 demonstrated anti-obesity efficacy comparable to Semaglutide.

Therefore, APT3711 could be administered SQ less frequently than existing SQ anti-obesity drugs (potentially once-per-month).

Novel Insulin Analog APT3598

● APT3598 controls glucose better than Novo Nordisk’s Insulin Icodec in Sprague-Dawley rats, M model, more consistently and for a longer time.

● APT3598 has high potential for a pharmacologically better once-weekly injection drug as compared to Insulin Icodec.

● Insulin Icodec was recently approved as a once-a-weekly injection in the EU and China but not in the USA.

● The global 2023 sales of commercially approved once-daily insulin Degludec and insulin Glargine were $815 million and >$2 billion, respectively.

● The global insulin market is >$40 billion and still growing with the increasing diabetes population.

Contact Ampeptec:

Simrat Singh, Chief Operating Officer, E-mail: simrat.singh@ampeptec.com

We are seeking business partners to help develop highly promising drugs.

With global annual sales of GLP-1 drugs projected to exceed $100 billion, APT3711 represents a significant opportunity in this rapidly growing market.

With the increasing diabetes population, APT3598 has unique superiority compared to other insulin analog.